The EU’s Pharmaceutical Strategy must do more to support nanomedicines and protect patient safety. Here’s why.
Mike Isles is the Executive Director of the European Alliance for Access to Safe Medicines (EAASM).
If Europe is to make its world-leading pharmaceutical sector fit for the future, a regulatory framework that supports innovative types of treatments and protects patient safety is imperative. The European Commission’s new Pharmaceutical Strategy, published in the midst of a pandemic consuming all our attention, could provide a great opportunity for a step in the right direction.
Here we focus on a highly significant innovative technology in the medical field: nanomedicine. Nanomedicine is an exciting and growing field, offering potential solutions to several treatment challenges, notably in key areas such as cancer, cardiovascular and neurodegenerative diseases.